These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 9857856)
1. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. van Veldhuisen DJ; Genth-Zotz S; Brouwer J; Boomsma F; Netzer T; Man In 'T Veld AJ; Pinto YM; Lie KI; Crijns HJ J Am Coll Cardiol; 1998 Dec; 32(7):1811-8. PubMed ID: 9857856 [TBL] [Abstract][Full Text] [Related]
2. Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. Hosoya K; Ishimitsu T Cardiovasc Drug Rev; 2002; 20(2):93-110. PubMed ID: 12177688 [TBL] [Abstract][Full Text] [Related]
3. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Pinto YM; van Veldhuisen DJ; Tjon-Ka-Jie RT; Rooks G; Netzer T; Lie KI Eur J Clin Pharmacol; 1996; 50(4):265-8. PubMed ID: 8803516 [TBL] [Abstract][Full Text] [Related]
4. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Gheorghiade M; Hall VB; Jacobsen G; Alam M; Rosman H; Goldstein S Circulation; 1995 Oct; 92(7):1801-7. PubMed ID: 7671364 [TBL] [Abstract][Full Text] [Related]
5. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369 [TBL] [Abstract][Full Text] [Related]
6. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Soejima H; Ogawa H; Yasue H; Suefuji H; Kaikita K; Nishiyama K Clin Cardiol; 1997 May; 20(5):441-5. PubMed ID: 9134274 [TBL] [Abstract][Full Text] [Related]
7. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Oshima S; Ogawa H; Mizuno Y; Yamashita S; Noda K; Saito T; Sumida H; Suefuji H; Kaikita K; Soejima H; Yasue H Am Heart J; 1997 Nov; 134(5 Pt 1):961-6. PubMed ID: 9398110 [TBL] [Abstract][Full Text] [Related]
9. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure. Szabó BM; van Veldhuisen DJ; van der Burgh PH; Kruik J; Girbes AR; Lie KI J Card Fail; 1996 Sep; 2(3):185-92. PubMed ID: 8891856 [TBL] [Abstract][Full Text] [Related]
10. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. Kinugawa T; Ogino K; Kato M; Furuse Y; Shimoyama M; Mori M; Endo A; Kato T; Omodani H; Osaki S; Miyakoda H; Hisatome I; Shigemasa C Gen Pharmacol; 1998 Jul; 31(1):93-9. PubMed ID: 9595286 [TBL] [Abstract][Full Text] [Related]
11. Systemic, regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers. Démolis P; Annane D; Duhazé P; Giudicelli JF Fundam Clin Pharmacol; 1994; 8(1):80-9. PubMed ID: 8181800 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Harder S; Thürmann PA Br J Clin Pharmacol; 1997 May; 43(5):475-80. PubMed ID: 9159562 [TBL] [Abstract][Full Text] [Related]
13. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Harder S; Thürmann PA; Ungethüm W Br J Clin Pharmacol; 1998 Apr; 45(4):377-80. PubMed ID: 9578185 [TBL] [Abstract][Full Text] [Related]
14. Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. Kinugawa T; Osaki S; Kato M; Ogino K; Shimoyama M; Tomikura Y; Igawa O; Hisatome I; Shigemasa C Clin Exp Pharmacol Physiol; 2002 Dec; 29(12):1060-5. PubMed ID: 12390293 [TBL] [Abstract][Full Text] [Related]
15. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Murdoch DR; McDonagh TA; Byrne J; Blue L; Farmer R; Morton JJ; Dargie HJ Am Heart J; 1999 Dec; 138(6 Pt 1):1126-32. PubMed ID: 10577444 [TBL] [Abstract][Full Text] [Related]
16. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. Sidik NP; Solomon SD; Latini R; Maggioni AP; Wright M; Gimpelewicz CR; Pitt B; McMurray JJ Cardiovasc Drugs Ther; 2011 Aug; 25(4):315-21. PubMed ID: 21779784 [TBL] [Abstract][Full Text] [Related]
17. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors. Valdemarsson S; Edvinsson L; Ekman R; Hedner P; Sjöholm A J Intern Med; 1991 Oct; 230(4):325-31. PubMed ID: 1717629 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL; Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409 [TBL] [Abstract][Full Text] [Related]
20. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment? Lim PO; MacFadyen RJ; Struthers AD Heart; 2000 Mar; 83(3):257-61. PubMed ID: 10677399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]